Ramu Ramucirumab (CYRAMZA)
Description: <b>Ramucirumab (CYRAMZA)</b> is a fully human IgG1 monoclonal antibody that binds VEGFR-2 (KDR/Flk-1) on endothelial cells and blocks VEGF-A/VEGF-C/VEGF-D from activating the receptor, thereby suppressing VEGFR-2 phosphorylation and downstream pro-angiogenic signaling (endothelial proliferation, migration, survival, and vascular permeability). Clinically, it’s used as an anti-angiogenic therapy across multiple solid tumors (labelled indications include advanced/metastatic gastric/GEJ adenocarcinoma, NSCLC in specific combinations/settings, metastatic colorectal cancer in combination therapy, and AFP-high hepatocellular carcinoma after prior therapy).<br>
<br>
Pathways/axes ramucirumab functionally down-modulates (via VEGFR-2 blockade)<br>
-VEGF ligand → VEGFR-2 angiogenesis axis (core target): vessel sprouting, endothelial survival, migration, permeability.<br>
-PI3K → AKT (PKB) survival signaling downstream of VEGFR-2 (endothelial cell survival/anti-apoptosis).<br>
-RAS → RAF → MEK → ERK (MAPK) proliferation signaling downstream of VEGFR-2 (endothelial proliferation).<br>
-PLCγ → PKC signaling downstream of VEGFR-2 (linked to permeability and other endothelial responses).<br>
-Src-family kinases / TSAd–Src modules and FAK/integrin–cytoskeleton signaling (migration, adhesion, barrier regulation).<br>
-eNOS → nitric oxide (NO) signaling (vascular tone/permeability; intersects with Src and PLCγ signaling).
-Vascular permeability & “vascular normalization” effects that can secondarily modulate tumor hypoxia/HIF programs and immune cell trafficking/antitumor immunity in the microenvironment (context-dependent).<br>
<br>